Natera (NASDAQ:NTRA) Stock Rating Reaffirmed by Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Natera (NASDAQ:NTRA) in a research note released on Friday, Benzinga reports. They currently have a $150.00 price objective on the medical research company’s stock.

A number of other brokerages have also recently weighed in on NTRA. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a buy rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price target on Natera from $130.00 to $145.00 and gave the stock a buy rating in a research report on Tuesday, August 27th. BTIG Research increased their price objective on Natera from $125.00 to $135.00 and gave the company a buy rating in a research report on Friday, August 9th. TD Cowen upped their target price on shares of Natera from $137.00 to $145.00 and gave the company a buy rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group assumed coverage on shares of Natera in a research report on Monday, June 3rd. They issued a buy rating and a $142.00 price target on the stock. One investment analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $120.07.

Natera Stock Up 1.1 %

NTRA stock opened at $126.51 on Friday. Natera has a 12-month low of $36.90 and a 12-month high of $128.28. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company has a market cap of $15.65 billion, a price-to-earnings ratio of -40.55 and a beta of 1.53. The company has a 50 day moving average of $112.73 and a two-hundred day moving average of $103.97.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.97) earnings per share. On average, equities analysts anticipate that Natera will post -1.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 499 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the sale, the chief financial officer now owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO Michael Burkes Brophy sold 499 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the transaction, the chief financial officer now owns 77,418 shares in the company, valued at $8,314,693.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at $34,783,235.41. The disclosure for this sale can be found here. Insiders have sold a total of 86,283 shares of company stock valued at $9,523,685 in the last 90 days. 7.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in NTRA. Itau Unibanco Holding S.A. bought a new stake in shares of Natera during the second quarter worth $28,000. Principal Securities Inc. bought a new position in Natera during the 4th quarter worth about $32,000. Quarry LP raised its stake in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. Finally, YHB Investment Advisors Inc. acquired a new position in shares of Natera during the first quarter worth about $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.